US › Healthcare

INmune Bio Inc (INMB)

US · Healthcare · Biotechnology

$1.91+3.24%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-5.4M
Profit YoY
+44.5%
EPS
$-0.20
EPS estimate
$-0.18

EPS came in at -0.20 against a street estimate of -0.18 — a miss of 11.1%.

Key statistics

Market cap
$46.5M
Forward P/E
0.0
P/B
2.37
Book value
$0.74
EPS (TTM)
$-1.63
52-week high
$2.85
52-week low
$1.09
50-day MA
$1.57
200-day MA
$1.54
Beta
0.98

Analyst view

Analysts rate INmune Bio Inc a buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.00.

Shareholding

Insiders
11.23%
Institutions
19.57%

Largest institutional holders

FundStake
BlackRock Inc4.49%
Vanguard Capital Management, LLC2.58%
Geode Capital Management, LLC1.86%
State Street Corp1.09%
AQR Capital Management LLC1.02%
UBS Group AG0.95%
The Goldman Sachs Group Inc0.87%
Susquehanna International Group, LLP0.73%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for INmune Bio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.